Physician profile
Thomas Coleman
NPI 1699333815
$3,403.79
in general payments reported to CMS, 2019-2025
30 companies · $1,061 in 2025
The $1,061 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $420 · 2023: $997 · 2024: $925 · 2025: $1,061.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,984.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,983.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $330.97 | 2023-2025 | Cutaquig, Panzyga |
| Astrazeneca Pharmaceuticals Lp | $307.53 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $300.16 | 2023-2025 | Vraylar, Viberzi, Linzess |
| Glaxosmithkline, LLC. | $273.41 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $242.52 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $218.81 | 2023-2025 | Gemtesa |
| Lilly USA, LLC | $213.71 | 2022-2025 | Zepbound, Mounjaro, Kisunla |
| Bayer Healthcare Pharmaceuticals INC. | $177.11 | 2022-2025 | |
| Immunitybio, INC. | $158.26 | 2025 | |
| Janssen Pharmaceuticals, INC | $155.28 | 2023-2025 | Spravato |
| Novartis Pharmaceuticals Corporation | $120.94 | 2022-2024 | |
| Novo Nordisk INC | $120.25 | 2022-2025 | Tresiba, Ozempic, Rybelsus |
| Stryker Corporation | $117.32 | 2022 | |
| Boston Scientific Corporation | $101.32 | 2024 | Spyglass Discover |
| Bioventus LLC | $81.75 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $70.62 | 2022 | |
| Amgen INC. | $57.50 | 2023-2025 | Evenity, Repatha, Otezla |
| Axsome Therapeutics, INC. | $50.43 | 2023-2024 | Auvelity |
| Xeris Pharmaceuticals, INC. | $41.89 | 2023 | Keveyis, Gvoke Hypopen |
| Procept Biorobotics Corporation | $41.51 | 2024 | Aquabeam System |
| Exact Sciences Corporation | $30.52 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $28.29 | 2024 | Dexcom G6 Transmitter |
| Calyxo, INC. | $26.26 | 2025 | Cvac Aspiration System |
| Daiichi Sankyo INC. | $22.38 | 2023 | Injectafer |
| Merck Sharp & Dohme LLC | $22.30 | 2022 | |
| Avyxa Pharma, LLC | $20.16 | 2025 | |
| Sanofi-Aventis U.S. LLC | $19.21 | 2022 | |
| Radius Health, INC. | $18.60 | 2025 | Tymlos |
| Inari Medical, INC. | $17.63 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.15 | 2023 | Ofev |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Coleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.